BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). JCO 1986;4:847-58. [DOI: 10.1200/jco.1986.4.6.847] [Cited by in Crossref: 89] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu R. Primary burkitt lymphoma of the chest wall. Case Rep Hematol 2012;2012:746098. [PMID: 22928128 DOI: 10.1155/2012/746098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Flexner JM, Stein RS, Greer JP. Outline of Treatment of Lymphoma Based on Hematologic and Clinical Stage with Expected End Results. Surgical Oncology Clinics of North America 1993;2:283-306. [DOI: 10.1016/s1055-3207(18)30582-9] [Reference Citation Analysis]
3 Aresu L, Agnoli C, Nicoletti A, Fanelli A, Martini V, Bertoni F, Marconato L. Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma. Front Vet Sci 2021;8:647009. [PMID: 33816589 DOI: 10.3389/fvets.2021.647009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Turro J, Singh P, Sarao MS, Tadepalli S, Cheriyath P. Adult Burkitt lymphoma- an Island between lymphomas and leukemias. J Community Hosp Intern Med Perspect 2019;9:25-8. [PMID: 30788071 DOI: 10.1080/20009666.2019.1574545] [Reference Citation Analysis]
5 Lin Y, Pan YH, Li MK, Zong XD, Pan XM, Tan SY, Guo YW. Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute pancreatitis: A case report. World J Gastroenterol 2021; 27(45): 7844-7854 [PMID: 34963746 DOI: 10.3748/wjg.v27.i45.7844] [Reference Citation Analysis]
6 Richert-Boe KE, Bagby GC Jr. Burkitt's lymphoma presenting as an endobronchial lesion. Am J Med 1988;85:864-6. [PMID: 2848416 DOI: 10.1016/s0002-9343(88)80038-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Pagano L, Caira M, Valentini CG, Fianchi L. Clinical aspects and therapy of sporadic burkitt lymphoma. Mediterr J Hematol Infect Dis 2009;1:e2009030. [PMID: 21416007 DOI: 10.4084/MJHID.2009.030] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, Tirumani SH. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging 2019;10:56. [PMID: 31115699 DOI: 10.1186/s13244-019-0733-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
9 Hwang YY, Loong F, Chung LP, Chim CS. Atypical Burkitt's lymphoma transforming from follicular lymphoma. Diagn Pathol 2011;6:63. [PMID: 21736761 DOI: 10.1186/1746-1596-6-63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010;92:732-43. [PMID: 21120644 DOI: 10.1007/s12185-010-0728-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]